Age-related macular degeneration is a potentially progressive maculopathy.
Characterised by drusen formation, macular pigmentary changes, geographic atrophy, and neovascularisation of the choriocapillaris with exudation.
Sudden-onset of blurring or distortion of vision is often the presenting symptom in the neovascular form.
Leading cause of adult blindness in industrialised nations.
Typically affects people aged >55 years.
Diagnosis and treatment are highly specialised and involve consultation with a retinal specialist.
Age-related macular degeneration (AMD) is a potentially progressive maculopathy. It is characterised by distinct clinical stages including early and intermediate AMD with drusen (yellow deposits under the retina made up of lipids and proteins) and macular pigmentary changes, usually associated with normal or near-normal vision; and late AMD, which is associated with a decrease or loss of central vision. Late (or advanced) AMD has two forms: geographic atrophy (or 'atrophic' or 'dry' AMD) and neovascular AMD (or 'wet' or 'exudative' AMD). Geographic atrophy is a chronic progressive degeneration of the macula; degeneration commences at the level of the retinal pigment epithelium, which is lost in the late stages with associated thinning and degeneration of the neurosensory retina. Choroidal neovascularisation refers to the abnormal growth of blood vessels from the vascular layer of the eye (choroid) to the neurosensory retina.
People with small drusen (<63 micrometres), also termed drupelets, are considered to have normal ageing changes. People with medium-sized drusen (≥63 to <125 micrometres) in the absence of pigmentary changes are defined as having early AMD. People with large drusen (≥125 micrometres) or pigmentary abnormalities and at least medium-sized drusen are defined as having intermediate AMD.
Five-year risks of progressing to late AMD are estimated to increase from 0.5% for normal ageing changes up to 50% risk for intermediate AMD.
History and exam
Sajjad Mahmood, MA, MB BCHIR, FRCOphth
Consultant Ophthalmologist and Medical Retina Specialist
Honorary Clinical Lecturer
Division of Pharmacy and Optometry
Faculty of Biology, Medicine, and Health
University of Manchester
SM has done consultancy work and received honoraria for lecturing and travel from Bayer Pharmaceuticals and Novartis. He has also been a principal investigator for clinical trials on behalf of Bayer, Novartis, and Roche.
Mr Sajjad Mahmood would like to gratefully acknowledge Dr Leon Charkoudian, Dr Joshua L. Dunaief, and Professor Paul Bishop, the previous contributors to this topic. LC and JLD declare that they have no competing interests. PB has undertaken research activities and received research grants (from charities and the Medical Research Council) that relate to basic mechanisms underpinning age-related macular degeneration. He is an inventor on a patent for a new treatment for age-related macular degeneration filed by the University of Manchester. He does not believe that any of these activities are competing interests with respect to the content of the topic.
Sharon Fekrat, MD
Duke University Eye Center
SF declares that she has no competing interests.
Use of this content is subject to our disclaimer